{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:20:17Z","timestamp":1789968017561,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.beha.2017.11.002","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T21:31:48Z","timestamp":1511386308000},"page":"15-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Risk stratification in follicular lymphoma"],"prefix":"10.1016","volume":"31","author":[{"given":"Carla","family":"Casulo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2017.11.002_bib1","doi-asserted-by":"crossref","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.beha.2017.11.002_bib2","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/annonc\/mdv375","article-title":"Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Studydagger","volume":"26","author":"Casulo","year":"2015","journal-title":"Annals of oncology : Off J Eur Soc Med Oncol\/ESMO"},{"issue":"6","key":"10.1016\/j.beha.2017.11.002_bib3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2017.11.002_bib4","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2017.11.002_bib5","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2017.11.002_bib6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mds429","article-title":"Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices","volume":"24","author":"Nooka","year":"2013","journal-title":"Ann Oncol Off J Eur Soc Med Oncol\/ESMO"},{"issue":"27","key":"10.1016\/j.beha.2017.11.002_bib7","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"19","key":"10.1016\/j.beha.2017.11.002_bib8","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"9873","key":"10.1016\/j.beha.2017.11.002_bib9","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.beha.2017.11.002_bib10","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the fondazione italiana linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.002_bib11","series-title":"Sequential RCHOP, radioimmunotherapy and rituximab maintenance improves early outcomes in advanced stage follicular lymphoma: 5 Year outcomes from SWOG 0801 american society of hematology annual meeting, 2016, absract #614","author":"Barr","year":"2016"},{"key":"10.1016\/j.beha.2017.11.002_bib12","doi-asserted-by":"crossref","unstructured":"Salles G SJ, Feugier P, et\u00a0al. Updated 6 Year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy. 2013 122:509 2013.","DOI":"10.1182\/blood.V122.21.509.509"},{"issue":"23","key":"10.1016\/j.beha.2017.11.002_bib13","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2017.11.002_bib14","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.beha.2017.11.002_bib15","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.002_bib16","author":"Lansigan","year":"2016"},{"key":"10.1016\/j.beha.2017.11.002_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group","author":"Barrington","year":"2014","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"23","key":"10.1016\/j.beha.2017.11.002_bib18","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","article-title":"Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants","volume":"29","author":"Trotman","year":"2011","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2017.11.002_bib19","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","article-title":"The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi","volume":"24","author":"Luminari","year":"2013","journal-title":"Ann Oncol Off J Eur Soc Med Oncol\/ESMO"},{"issue":"35","key":"10.1016\/j.beha.2017.11.002_bib20","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","article-title":"Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS","volume":"30","author":"Dupuis","year":"2012","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2017.11.002_bib21","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.beha.2017.11.002_bib22","article-title":"Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials","author":"Shi","year":"2016","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2017.11.002_bib23","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/annonc\/mdw185","article-title":"Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL","volume":"27","author":"Koch","year":"2016","journal-title":"Ann Oncol Off J Eur Soc Med Oncol\/ESMO"},{"issue":"2","key":"10.1016\/j.beha.2017.11.002_bib24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2141.2011.08942.x","article-title":"Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times","volume":"156","author":"Wahlin","year":"2012","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.beha.2017.11.002_bib25","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N.\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.beha.2017.11.002_bib26","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1182\/blood-2007-10-115915","article-title":"Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling","volume":"111","author":"Byers","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2017.11.002_bib27","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood-2005-04-1565","article-title":"Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)","volume":"106","author":"Farinha","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2017.11.002_bib28","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","article-title":"High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma","volume":"108","author":"Carreras","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2017.11.002_bib29","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1182\/blood-2005-08-3376","article-title":"Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma","volume":"107","author":"Yang","year":"2006","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.beha.2017.11.002_bib30","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2006.06.4642","article-title":"Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome","volume":"24","author":"Lee","year":"2006","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2 Pt 1","key":"10.1016\/j.beha.2017.11.002_bib31","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/1078-0432.CCR-06-1734","article-title":"CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma","volume":"13","author":"Wahlin","year":"2007","journal-title":"Clin cancer Res Off J Am Assoc Cancer Res"},{"issue":"7360","key":"10.1016\/j.beha.2017.11.002_bib32","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"7337","key":"10.1016\/j.beha.2017.11.002_bib33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.beha.2017.11.002_bib34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.beha.2017.11.002_bib35","doi-asserted-by":"crossref","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.beha.2017.11.002_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","author":"Meignan","year":"2016","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2017.11.002_bib37","doi-asserted-by":"crossref","first-page":"e2017010","DOI":"10.4084\/mjhid.2017.010","article-title":"Is there a role for minimal residual disease monitoring in follicular lymphoma in the chemo-immunotherapy era?","volume":"9","author":"Gritti","year":"2017","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"24","key":"10.1016\/j.beha.2017.11.002_bib38","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","article-title":"Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial","volume":"20","author":"Galimberti","year":"2014","journal-title":"Clin cancer Res Off J Am Assoc Cancer Res"},{"issue":"25","key":"10.1016\/j.beha.2017.11.002_bib39","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2016-03-635219","article-title":"Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma","volume":"127","author":"Roschewski","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.002_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T15:57:19Z","timestamp":1603382239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692617300798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1521692617300798"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2017.11.002","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk stratification in follicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2017.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}